Pharma Two B Presents Late-Breaker Abstract on Positive Efficacy and Safety Data of P2B001 from Phase 3 Trial at American Academy of Neurology (AAN) Annual Meeting
REHOVOT, Israel, April 05, 2022 (GLOBE NEWSWIRE) — Pharma Two B Ltd., a privately held company developing innovative therapeutics based on reformulation and combinations of previously approved drugs for neurological indications, today announced that the efficacy and safety data from its recently completed Phase 3, randomized controlled trial of P2B001 in the management of early Parkinson’s … Read more